Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus, followed by a twin strep tag. The protein has a calculated MW of 59.5 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>92% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 20 mM Tris, 150 mM NaCl, pH8.0 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human Akt1, His,Strep II Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 92%.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Capivasertib | AZD-5363 | Approved | Astex Pharmaceuticals Inc, Cancer Research Technology, The Institute Of Cancer Research, London | Truqap | United States | Breast Neoplasms | Astrazeneca Pharmaceuticals Lp | 2023-11-16 | Uterine Neoplasms; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Hormone-Sensitive Prostate Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Glioma; Metastatic breast cancer; Urinary Bladder Neoplasms; Lymphoma; Lung Neoplasms; Thyroid Neoplasms; HR-positive breast cancer; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Uterine Cervical Neoplasms; Melanoma; Esophageal Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Rectal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Colonic Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Afuresertib | GSK-21110183; GSK-2110183B; GSK-2110183C; LAE002; ASB-183; GSK-2110183; LAE-002 | Phase 3 Clinical | Novartis Pharma Ag, Glaxosmithkline Plc | Breast Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Endometrial Neoplasms; Metastatic breast cancer; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Histiocytosis, Langerhans-Cell; Hematologic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Triple Negative Breast Neoplasms; Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
Ipatasertib | RG-7440; GCD-0068; GDC-0068; RO-5532961 | Phase 3 Clinical | Array Biopharma, Genentech Inc | Lymphoma, Non-Hodgkin; Hepatic Insufficiency; Neoplasms, Unknown Primary; Laryngeal Neoplasms; Paranasal Sinus Diseases; Endometrial Neoplasms; Carcinoma, Squamous Cell; Metastatic breast cancer; Paranasal Sinus Neoplasms; Mouth Neoplasms; Genital Neoplasms, Female; Fallopian Tube Neoplasms; Urogenital Neoplasms; Lymphoma; Lip Neoplasms; Carcinoma, Endometrioid; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Hypopharyngeal Neoplasms; Solid tumours; Head and Neck Neoplasms; Ovarian Neoplasms; Cystadenocarcinoma, Serous; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Neoplasm, Residual; Glioblastoma; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Oropharyngeal Neoplasms; Peritoneal Neoplasms | Details |
SR-0379 | SR-0379 | Phase 3 Clinical | FunPep Co Ltd | Skin Ulcer | Details |
Triciribine Phosphate | NSC-154020; PTX-002; API-2; TCN-P; VQD-002-ORAL; VQD-002; NSC-280594; PTX-200 | Phase 2 Clinical | National Cancer Institute | Hematologic Neoplasms; Leukemia; Ovarian Neoplasms; Neoplasms; Breast Neoplasms | Details |
Miransertib | MK-7075; ARQ-092 | Phase 2 Clinical | Arqule Inc | Ovarian Neoplasms; Solid tumours; Proteus Infections; Neoplasms; PIK3CA-Related Overgrowth Spectrum; Lymphoma; Endometrial Neoplasms; Proteus Syndrome | Details |
Iopofosine I-131 | CLR-131; NM404; (131)I-CLR1404; 131I-NM-404; HOT; CLR1404 I-131; I-131-CLR1404; (131)I-NM 404 | Phase 2 Clinical | University Of Michigan | Neuroblastoma; Leukemia, Lymphocytic, Chronic, B-Cell; Central Nervous System Lymphoma; Glioma; Lymphoma; Waldenstrom Macroglobulinemia; Diffuse Intrinsic Pontine Glioma; Brain Neoplasms; Osteosarcoma; Lymphoma, B-Cell, Marginal Zone; Sarcoma, Ewing; Lymphoma, Mantle-Cell; Multiple Myeloma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Head and Neck Neoplasms; Solid tumours; Rhabdomyosarcoma | Details |
Ursolic Acid | NSC-167406; NSC-4060 | Phase 2 Clinical | University Of Guadalajara | Prostatic Neoplasms; Carcinoma, Hepatocellular; Sarcopenia; Lung Neoplasms; Muscular Atrophy; Colorectal Neoplasms; Quadriplegia; Cholangitis, Sclerosing; Breast Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Insulin Resistance; Metabolic Syndrome; Paraplegia; Spinal Cord Injuries; Stomach Neoplasms | Details |
Uprosertib/Trametinib Dimethyl Sulfoxide | Phase 2 Clinical | Novartis Pharma Ag | Endometrial Neoplasms; Leukemia, Myeloid, Acute; Uterine Cervical Neoplasms | Details | |
Selumetinib sulfate/MK-2206 | Phase 2 Clinical | Astrazeneca Plc, Merck & Co Inc | Rectal Neoplasms; Triple Negative Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lung Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details | |
Uprosertib | GSK-795; GSK-2141795; GSK-2141795C; UPB-795 | Phase 2 Clinical | Glaxosmithkline Plc, Novartis Pharma Ag, National Cancer Institute | Solid tumours; Hematologic Neoplasms; Skin Melanoma; Neoplasms; Triple Negative Breast Neoplasms; Uveal melanoma; Multiple Myeloma; Adenocarcinoma, Clear Cell; Breast Neoplasms; Endometrial Neoplasms; Uterine Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Melanoma; Uterine Cervical Neoplasms | Details |
RX-0301 | WGI-0301; RX-0201改良型; HC0301; RX-0201 nanoliposomal; RX-0201 Nano; RX-0201-N; RX-0301 | Phase 2 Clinical | Rexahn Pharmaceuticals Inc | Liver Neoplasms; Solid tumours; Carcinoma, Hepatocellular | Details |
MK-2206 | MK2206; MK-2206; BIND-2206; NSC-749607 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Colorectal Neoplasms; Lymphoma, T-Cell; Waldenstrom Macroglobulinemia; Intraocular Lymphoma; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Glioma; Leukemia, Myelomonocytic, Juvenile; Lymphoma, T-Cell, Cutaneous; Neoplasms, Gonadal Tissue; Lung Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Peritoneal Neoplasms; Adenocarcinoma, Bronchiolo-Alveolar; Sezary Syndrome; Bile Duct Neoplasms; Prostatic Neoplasms; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Adenocarcinoma; Leukemia, T-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Large Granular Lymphocytic; Leukemia, Prolymphocytic; Breast Neoplasms, Male; Mycosis Fungoides; Carcinoma, Hepatocellular; Central Nervous System Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Cholangiocarcinoma; Angioimmunoblastic T-cell Lymphoma; Endometrial Neoplasms; Lymphoma, Non-Hodgkin; Thymoma; Gallbladder Neop | Details |
NTQ-1062 | NTQ-1062; NTQ1062 | Phase 2 Clinical | Nanjing Zhengda Tianqing Pharmaceutical Co Ltd | Solid tumours; Breast Neoplasms; HR-positive breast cancer | Details |
HZB-0071 | HZB-0071 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Heilongjiang Zbd Pharmaceutical Co Ltd | Neoplasms | Details |
Rupitasertib | DIACC3010; M-2698; MSC-2363318A; DIACC-3010 | Phase 1 Clinical | Emd Serono Inc | Solid tumours; Stomach Neoplasms; Glioblastoma; Breast Neoplasms | Details |
Honokiol | HU-002; JRF-101 | Phase 1 Clinical | Anacor Pharmaceuticals Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Gingival Diseases; Carcinoma, Non-Small-Cell Lung | Details |
CMX-2043 | LIP-EA; CMX-2043; R-LIP-EA-OH | Phase 1 Clinical | Ischemix Llc | Brain Injuries, Traumatic; Angina, Unstable; Coronary Artery Disease; Cardiovascular Diseases; Non-ST Elevated Myocardial Infarction | Details |
ALTA-2618 | ALTA-2618 | Phase 1 Clinical | Alterome Therapeutics Inc | Solid tumours; Neoplasms; Breast Neoplasms; Endometrial Neoplasms; Neoplasm Metastasis | Details |
Hu-7691 | Hu-7691 | Phase 1 Clinical | Zhejiang University | Solid tumours; Neoplasms | Details |
Oxysterols (Intsel Chimos) | Clinical | Centre National De La Recherche Scientifique (Cnrs) | Glioma | Details |
This web search service is supported by Google Inc.